newsfilter
← Latest News
GlobeNewswire·

Neoleukin Therapeutics Announces Year End 2020 Financial Results

- Anticipating first patient for NL-201 Phase 1 Trial in 1H21 - - Cash and cash equivalents of $192.6 million expected to fund operations into 2023 - - Company to host Conference Call Today,...